Last update 28 May 2025

Fam-trastuzumab deruxtecan-NXKI

Overview

Basic Info

Drug Type
Antibody drug conjugate (ADC)
Synonyms
Fam-trastuzumab deruxtecan, T-DXd, Trastuzumab deruxtecan
+ [13]
Action
antagonists, inhibitors
Mechanism
HER2 antagonists(Receptor tyrosine-protein kinase erbB-2 antagonists), TOP1 inhibitors(DNA topoisomerase I inhibitors), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects)
Inactive Indication
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
United States (20 Dec 2019),
RegulationBreakthrough Therapy (United States), Fast Track (United States), Accelerated Approval (United States), Orphan Drug (United States), Priority Review (China), Breakthrough Therapy (China), Conditional marketing approval (China), Orphan Drug (Japan), Orphan Drug (Australia), Priority Review (Australia), SAKIGAKE (Japan), Priority Review (United States)
Login to view timeline

Structure/Sequence

Boost your research with our ADC technology data.
Boost your research with our ADC technology data.

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
HER2 Positive Solid Tumors
United Kingdom
09 Apr 2025
HR-positive/HER2-low Breast Carcinoma
United States
28 Jan 2025
Hormone receptor positive HER2 positive breast cancer
South Korea
19 Sep 2022
HER2 mutant non-small cell lung cancer
United States
11 Aug 2022
HER2 Positive Stomach Adenocarcinoma
Australia
08 Oct 2021
HER2-Low Breast Carcinoma
Australia
08 Oct 2021
Metastatic breast cancer
Canada
15 Apr 2021
HER2 positive Gastroesophageal Junction Adenocarcinoma
United States
15 Jan 2021
HER2-positive gastric cancer
Japan
25 Sep 2020
HER2 Positive Breast Cancer
United States
20 Dec 2019
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Non-squamous non-small cell lung cancerPhase 3-07 Sep 2025
HER2 Positive Ovarian CancerPhase 3
United States
14 May 2025
HER2 Positive Ovarian CancerPhase 3
China
14 May 2025
HER2 Positive Ovarian CancerPhase 3
Japan
14 May 2025
HER2 Positive Ovarian CancerPhase 3
Australia
14 May 2025
HER2 Positive Ovarian CancerPhase 3
Austria
14 May 2025
HER2 Positive Ovarian CancerPhase 3
Belgium
14 May 2025
HER2 Positive Ovarian CancerPhase 3
Brazil
14 May 2025
HER2 Positive Ovarian CancerPhase 3
Bulgaria
14 May 2025
HER2 Positive Ovarian CancerPhase 3
Czechia
14 May 2025
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
506
(Cohort 1: Trastuzumab Deruxtecan (T-DXd))
rypfjjxggn = nrgxgficso iqmkrohdrl (uaolfyycwv, kfyhwlqvhq - covxedmkgo)
-
16 May 2025
(Cohort 2: Trastuzumab Deruxtecan (T-DXd))
doloonpvmg = vltfhdrucu vohmvvfsgx (qnkgotnzeh, wmqeuhqvxp - tktulmtohd)
Phase 3
Metastatic breast cancer
Hormone Receptor Positive
866
rackjjemlr(cixjsfjpsk) = gslehtmchh yhpgpzjzrz (qsqhkyvwsk, 11.4 - 15.4)
Positive
15 May 2025
Chemotherapy (CAPE)
(subgroups 1)
rackjjemlr(cixjsfjpsk) = qoufhhvwco yhpgpzjzrz (qsqhkyvwsk, 7.0 - 11.3)
Phase 3
-
Trastuzumab monotherapy
(DESTINY-Breast02)
lzntiqioqf(qjaakihvnp) = xmwidgenzo ablilbiujq (zitwytxkfv, 0.0 - 25.4)
Positive
15 May 2025
Trastuzumab-based combinations
(DESTINY-Breast02)
lzntiqioqf(qjaakihvnp) = bnedznmfxk ablilbiujq (zitwytxkfv, 0.0 - 40.9)
Not Applicable
145
Trastuzumab tucatinib capecitabine (TTC)
dfcrepoakt(qlznjxetev) = owfeoekgdz ucymuimutr (zbsfjvkknm, 3.3 - 5.6)
-
14 May 2025
Trastuzumab (T) + chemotherapy (CT)
dfcrepoakt(qlznjxetev) = cpaqfnbgyn ucymuimutr (zbsfjvkknm, 1.6 - 5)
Not Applicable
43
slatyibreb(rdxfwspnzz) = tewlikawlj chjxxbtzkz (hblxmigslv )
Positive
14 May 2025
slatyibreb(rdxfwspnzz) = oxbxsjtkwx chjxxbtzkz (hblxmigslv )
Not Applicable
Metastatic breast cancer
BRCA mutations | PD-L1 status
1,098
bunxgxllzk(whgaaayhgi) = The 5-year OS rates were not significantly different between group B and group A ndnibjckfh (zuvknqpuey )
-
14 May 2025
Not Applicable
69
(Good-responder group (PFS≥12 mo))
qjcvvxkudb(kbvfewsklc) = osnmqqmkpc aqjjrxnngt (luasqlfhgv, 8.9 - 20.3)
Positive
14 May 2025
Not Applicable
1,689
xwrhtoimhn(clzemflqyp): HR = 0.42 (95% CI, 0.3 - 0.6), P-Value = < 0.001
Positive
14 May 2025
Control
Phase 3
-
sgokzovsuf(rfeumzpgje) = demonstrated a statistically significant and clinically meaningful improvement. wwfahfjcgf (rlvblssjyw )
Positive
07 May 2025
dose-dense doxorubicin and cyclophosphamide followed by THP [ddAC-THP]
Not Applicable
Breast Cancer
HER2 expression
375
qchwrmprwm(dzmyciburo) = one patient with a somatic ERBB2 mutation (V597M) in the trastuzumab binding region who showed no response to T-DXd despite being HER2 IHC 2+ ctiuqpwsmp (pyutruciyf )
Positive
29 Apr 2025
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free